GlassScriptPhysician profile
Jill Dg Hoffman
NPI 1861924680
$12,395.94
in general payments reported to CMS, 2019-2025
38 companies · $2,697 in 2025
The $2,697 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $374 · 2021: $1,758 · 2022: $2,143 · 2023: $2,733 · 2024: $2,691 · 2025: $2,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,121.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,735.30 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,525.39 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,509.82 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,112.63 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $925.95 | 2023-2025 | |
| Amgen INC. | $809.10 | 2022-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $677.89 | 2021-2025 | |
| Exact Sciences Corporation | $418.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $415.57 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $377.88 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $366.20 | 2022-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $359.48 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $359.03 | 2021-2024 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.19 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $189.58 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.